non-HIV Flashcards
(30 cards)
MOA of the nucleoside analogues
compete with endogenous nucleosides for viral DNA polymerase, causing DNA chain termination
ADR of acyclovir
renal nephropathy (need hydration)
benefit of valcyclovir
prodrug with better bioavailability allows for less frequent dosing than acyclovir
use of penciclovir
only used for topical HSV1
famciclovir
prodrug of penciclovir, used for HSV and VZV
foscarnet MOA
pyrophosphate analogue that reversibly binds to viral DNA polymerase
ADR for foscarnet (4)
renal tubular crystallization (hydrate)
seizures
hypocalcemia (binds free Ca)
genital ulceration
MOA of ganciclovir
similar to acyclovir, analogue of guanine
when is ganciclovir used?
reserved for CMV infections
ADR of ganciclovir
bone marrow suppression, renal nephropathy
route of admin for ganciclovir vs valganciclovir
ganciclovir- IV
valganciclovir-PO
MOA of cidofovir
monophosphate analogue of deoxycytosine
special about cedofovir activation
does not require phosphorylation by viral kinase
when is cidofovir used
for CMV infections in patients with HIV when galciclovir and foscarnet are ineffective
precautions used with cidofovir
give with probenecid and saline infusion to prevent renal tubular secretion/toxicity
goals of HBV therapy
suppress HBV replication and slow progression of liver disease- will not eradicate infection, treatment is life long
first like agents for HBV (2)
tonfovir
entecavir
second line agents for HBV
interferons
ADR of interferons (3)
flu-like symptoms
bone marrow suppression
psych disturbances
goal of HCV treatment
eradication
which HCV genotype requires longer treatment
genotype 1- 48 weeks
first line therapy for HCV genotypes 2,3
interferon + ribivirin
first line therapy for HCV genotype 1
interferon + ribivirin + teleprevir or boceprevir
ADR of ribivirin
severe hemolytic anemia
